Premature labor: A state of platelet activation?

Journal of Perinatal Medicine

Volumn 36, Issue 5, 2008, Pages 377-387

  Erez, Offer ^a,b,e   Romero, Roberto ^a,b,e   Hoppensteadt, Debra ^c   Fareed, Jawed ^c   Chaiworapongsa, Tinnakorn ^b   Kusanovic, Juan Pedro ^a,b   Mazaki Tovi, Shali ^b   Gotsch, Francesca ^a   Than, Nandor Gabor ^a   Vaisbuch, Edi ^a   Kim, Chong Jai ^a,b   Espinoza, Jimmy ^a,b   Mittal, Pooja ^b   Hamill, Neil ^b   Nhan Chang, Chia Ling ^b   Mazor, Moshe ^d   Hassan, Sonia ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e HUTZEL HOSPITAL   (United States)

Author keywords

Coagulation; Inflammation; Labor; Platelet; Prematurity; sCD40L; Thrombin

Indexed keywords

CD40 LIGAND;

ADULT; AMNION FLUID; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; LABOR; MATERNAL PLASMA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CD40 LIGAND; CHORIOAMNIONITIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; OBSTETRIC LABOR, PREMATURE; PLATELET ACTIVATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 51549106151     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2008.082     Document Type: Article

References (140)

1. Ahlawat S, Pati HP, Bhatla N, Fatima L, Mittal S. Plasma platelet aggregating factor and platelet aggregation studies in pre-eclampsia. Acta Obstet Gynecol Scand. 1996;75:428-31.
2. Alacacioglu I, Ozcan MA, Piskin O, Yuksel F, Alacacioglu A, Demirkan F, et al. Increased concentration of soluble CD40 ligand in preeclampsia. Clin Appl Thromb Hemost. 2007;13:201-5.
3. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol. 1996;87:163-8.
4. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med. 2002;8:247-52.
5. Apoil PA, Kuhlein E, Robert A, Rubie H, Blancher A. HIGM syndrome caused by insertion of an AluYb8 element in exon 1 of the CD40LG gene. Immunogenetics. 2007;59:17-23.
6. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357:80-2.
7. Aruffo A, Hollenbaugh D, Wu LH, Ochs HD. The molecular basis of X-linked agammaglobulinemia, hyper-IgM syndrome, and severe combined immunodeficiency in humans. Curr Opin Hematol. 1994;1:12-8.
8. Ayhan A, Akkok E, Urman B, Yarali H, Dundar S, Kirazli S. Beta-thromboglobulin and platelet factor 4 levels in pregnancy and preeclampsia. Gynecol Obstet Invest. 1990;30:12-4.
9. Bagamery K, Landau R, Kvell K, Graham J. Different platelet activation levels in non-pregnant, normotensive pregnant, pregnancy-induced hypertensive and preeclamptic women. A pilot study of flow cytometric analysis. Eur J Obstet Gynecol Reprod Biol. 2005;121:117-8.
10. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van KC, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
11. Bar J, Zosmer A, Hod M, Elder MG, Sullivan MH. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. Thromb Haemost. 1997;78:1255-61.
12. Bloom AL. Physiology of blood coagulation. Haemostasis. 1990;20 (Suppl 1):14-29.
13. Bodis J, Torok A, Tinneberg HR. Hypothesis of preeclampsia requires inclusion of the role of platelets. Am J Obstet Gynecol. 1997;177:243-4.
14. Bolacchi F, Carbone M, Capozzi M, Ventura L, Cepparulo M, Niutta P, et al. Effect of different activation stimuli on the cytokine response of human macrophages to CD40L. Cytokine. 2001;16:121-5.
15. Brass LF, Zhu L, Stalker TJ. Minding the gaps to promote thrombus growth and stability. J Clin Invest. 2005;115:3385-92.
16. Brossart P, Grunebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:4238-47.
17. Brown NL, Alvi SA, Elder MG, Bennett PR, Sullivan MH. Regulation of prostaglandin production in intact fetal membranes by interleukin-1 and its receptor antagonist. J Endocrinol. 1998;159:519-26.
18. Chaiworapongsa T, Espinoza J, Yoshimatsu J, Kim YM, Bujold E, Edwin S, et al. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2002;11:368-73.
19. Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007;282:18307-17.
20. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428-34.
21. Chirmule N, Tazelaar J, Wilson JM. Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions. J Immunol. 2000;164:248-55.
22. Ciferska H, Horak P, Hermanova Z, Ordeltova M, Zadrazil J, Tichy T, et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol. 2007;26:723-8.
23. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation. 2003;108:2776-82.
24. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435-41.
25. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006;176:2617-24.
26. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut. 2007;56:1248-56.
27. Davi G, Ferroni P. CD40-CD40L interactions in platelet activation. Thromb Haemost. 2005;93:1011-2.
28. Del CI, Cruz MA, Zhang H, Lopez JA, fshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201:871-79.
29. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint BG. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature. 1993;361:541-3.
30. Dong YL, Gangula PR, Fang L, Yallampalli C. Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins. 1996;52:13-34.
31. Dongari-Bagtzoglou AI, Thienel U, Yellin MJ. CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent. Inflamm Res. 2003;52:18-25.
32. Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol. 2001;185:1059-63.
33. Elovitz MA, Wang Z, Chien EK, Rychlik DF, Phillippe M. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am J Pathol. 2003;163:2103-11.
34. Erez O, Hallak M, Luber A, Maymon E, Mazor M, Tomer A. Platelets activation marker as predictor of severe preeclampsia in patients with history of preeclampsia. Am J Obstet Gynecol. 2001;185:S175.
35. Erkinheimo TL, Saukkonen K, Narko K, Jalkanen J, Ylikorkala O, Ristimaki A. Expression of cyclooxygenase-2 and prostanoid receptors by human myometrium. J Clin Endocrinol Metab. 2000;85:3468-75.
36. Facchetti F, Appiani C, Salvi L, Levy J, Notarangelo LD. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J Immunol. 1995;154:6624-33.
37. Falco A, Romano M, Iapichino L, Collura M, Davi G. Increased soluble CD40 ligand levels in cystic fibrosis. J Thromb Haemost. 2004;2:557-60.
38. Felfernig-Boehm D, Salat A, Vogl SE, Murabito M, Felfernig M, Schmidt D, et al. Early detection of preeclampsia by determination of platelet aggregability. Thromb Res. 2000;98:139-46.
39. Gauchat JF, Aubry JP, Mazzei G, Life P, Jomotte T, Elson G, et al. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. 1993;315:259-66.
40. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993;365:340-3.
41. Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, et al. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol. 1995;25:863-5.
42. Gauchat JF, Mazzei G, Life P, Henchoz S, Peitsch MC, Aubry JP, et al. Human CD40 ligand: molecular cloning, cellular distribution and regulation of IgE synthesis. Res Immunol. 1994;145:240-4.
43. Gervasi MT, Chaiworapongsa T, Naccasha N, Blackwell S, Yoon BH, Maymon E, et al. Phenotypic and metabolic characteristics of maternal monocytes and granulocytes in preterm labor with intact membranes. Am J Obstet Gynecol. 2001;185:1124-9.
44. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun. 2006;26:165-71.
45. Graf D, Korthauer U, Mages HW, Senger G,Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol. 1992;22:3191-4.
46. Gross G, Imamura T, Vogt SK, Wozniak DF, Nelson DM, Sadovsky Y, et al. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. Am J Physiol Regul Integr Comp Physiol. 2000;278:R1415-23.
47. Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch. 2000;437:396-405.
48. Halim A, Kanayama N, el ME, Nakashima A, Bhuiyan AB, Khatun S, et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol. 1996;174:272-7.
49. Hanna N, Bonifacio L, Weinberger B, Reddy P, Murphy S, Romero R, et al. Evidence for interleukin-10-mediated inhibition of cyclo- oxygenase-2 expression and prostaglandin production in preterm human placenta. Am J Reprod Immunol. 2006;55:19-27.
50. Harlow FH, Brown MA, Brighton TA, Smith SL, Trickett AE, Kwan YL, et al. Platelet activation in the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2002;187:688-95.
51. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29:125-30.
52. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-4.
53. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-54.
54. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12:74-82.
55. Hertelendy F, Rastogi P, Molnar M, Romero R. Interleukin-1beta-induced prostaglandin E2 production in human myometrial cells: role of a pertussis toxin-sensitive component. Am J Reprod Immunol. 2001;45:142-7.
56. Hoffman DR, Romero R, Johnston JM. Detection of platelet-activating factor in amniotic fluid of complicated pregnancies. Am J Obstet Gynecol. 1990;162:525-8.
57. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 1992;11:4313-21.
58. Holmes VA, Wallace JM, Gilmore WS, McFaul P, Alexander HD. Soluble P-selectin levels during normal pregnancy: a longitudinal study. Br J Obstet Gynecol. 2002;109:997-1002.
59. Holthe MR, Lyberg T, Staff AC, Berge LN. Leukocyte-platelet interaction in pregnancies complicated with preeclampsia. Platelets. 2005;16:91-7.
60. Holthe MR, Staff AC, Berge LN, Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol. 2004;190:1128-34.
61. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest. 1992;89:1350-3.
62. Hutt R, Ogunniyi SO, Sullivan MH, Elder MG. Increased platelet volume and aggregation precede the onset of preeclampsia. Obstet Gynecol. 1994;83:146-9.
63. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92:1041-8.
64. Janes SL, Goodall AH. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci (Lond). 1994;86:731-9.
65. Janes SL, Kyle PM, Redman C, Goodall AH. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemost. 1995;74:1059-63.
66. Johansen B, Rakkestad K, Balboa MA, Dennis EA. Expression of cytosolic and secreted forms of phospholipase A(2) and cyclooxygenases in human placenta, fetal membranes, and chorionic cell lines. Prostaglandins Other Lipid Mediat. 2000;60:119-25.
67. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-87.
68. Karalis I, Nadar SK, Al YE, Blann AD, Lip GY. Platelet activation in pregnancy-induced hypertension. Thromb Res. 2005;116:377-83.
69. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol. 1996;156:3932-8.
70. Kimura K, Tsuda H, Kwangseok Y, Tamura N, Kanai Y, Kobayashi S. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis. Ther Apher Dial. 2005;9:64-8.
71. King AE, Kelly RW, Critchley HO, Malmstrom A, Sennstrom M, Phipps RP. Cd40 expression in uterine tissues: a key regulator of cytokine expression by fibroblasts. J Clin Endocrinol Metab. 2001;86:405-12.
72. Kniss DA. Cyclooxygenases in reproductive medicine and biology. J Soc Gynecol Investig. 1999;6:285-92.
73. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol. 2004;31:514-9.
74. Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker OP, et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 1997;176:461-9.
75. Konijnenberg A, van der Post JA, Mol BW, Schaap MC, Lazarov R, Bleker OP, et al. Can flow cytometric detection of platelet activation early in pregnancy predict the occurrence of preeclampsia? A prospective study. Am J Obstet Gynecol. 1997;177:434-42.
76. Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, Kolios G, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147-52.
77. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost. 2005;93:1137-46.
78. Laskowska M, Laskowska K, Leszczynska-Gorzelak B, Oleszczuk J. sCD40 ligand determined in maternal and umbilical cord blood in pregnancies complicated by preeclampsia with and without intrauterine growth retardation. Gynecol Obstet Invest. 2007;64:8-13.
79. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992;175:1091-101.
80. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology. 1999;92:11-6.
81. Lei XF, Ohkawara Y, Stampfli MR, Mastruzzo C, Marr RA, Snider D, et al. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin Invest. 1998;101:1342-53.
82. Leiberman JR, Hagay ZJ, Mazor M, Aharon M, Nathan I, Dvilansky A. Plasma and urine beta-thromboglobulin in severe preeclampsia. Arch Gynecol Obstet. 1988;243:165-8.
83. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131:47-54.
84. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol. 2000;20:2322-8.
85. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38:1229-37.
86. Lok CA, Nieuwland R, Sturk A, Hau CM, Boer K, Vanbavel E, et al. Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets. 2007;18:68-72.
87. Lopez-Granados E, Temmerman ST, Wu L, Reynolds JC, Follmann D, Liu S, et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci USA. 2007;%20;104:5056-61.
88. Louden KA, Broughton PF, Heptinstall S, Fox SC, Mitchell JR, Symonds EM. Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol. 1991;98:1239-44.
89. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis. 2003;18:142-7.
90. Luscher EF, Weber S. The formation of the haemostatic plug - a special case of platelet aggregation. An experiment and a survey of the literature. Thromb Haemost. 1993;70:234-7.
91. Macchi P, Villa A, Strina D, Sacco MG, Morali F, Brugnoni D, et al. Characterization of nine novel mutations in the CD40 ligand gene in patients with X-linked hyper IgM syndrome of various ancestry. Am J Hum Genet. 1995;56:898-906.
92. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 1993;7:516-22.
93. Marshall LS, Aruffo A, Ledbetter JA, Noelle RJ. The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39. J Clin Immunol. 1993;13:165-74.
94. Mause SF, von HP, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25:1512-8.
95. Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia - possible role of platelet activation. Thromb Haemost. 2001;86:1272-6.
96. Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH. Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening. Ultrasound Obstet Gynecol. 2002;19:443-8.
97. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani A, Sturn DH, Patsch JR, et al. CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin. Blood Coagul Fibrinolysis. 2005;16:105-10.
98. Mustard JF. The relationship between the structure of a thrombus or a hemostatic plug and the mechanisms involved in its formation. Thromb Diath Haemorrh. 1968;28 (Suppl):57-64; discussion 75-95:57-64.
99. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol. 1999;23:45-57.
100. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
101. Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol. 2005;95:452-6.
102. Norris LA, Gleeson N, Sheppard BL, Bonnar J. Whole blood platelet aggregation in moderate and severe preeclampsia. Br J Obstet Gynaecol. 1993;100:684-8.
103. O'Sullivan BP, Linden MD, Frelinger AL III, Barnard MR, Spencer-Manzon M, Morris JE, et al. Platelet activation in cystic fibrosis. Blood. 2005;105:4635-41.
104. Oron G, Ben-Haroush A, Hod M, Orvieto R, Bar J. Serum-soluble CD40 ligand in normal pregnancy and in preeclampsia. Obstet Gynecol. 2006;107:896-900.
105. Oxenius A, Campbell KA, Maliszewski CR, Kishimoto T, Kikutani H, Hengartner H, et al. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4q T cell functions. J Exp Med. 1996;183:2209-18.
106. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol. 2006;81:753-9.
107. Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens. 2006;24:117-21.
108. Pekonen F, Rasi V, Ammala M, Viinikka L,Ylikorkala O. Platelet function and coagulation in normal and preeclamptic pregnancy. Thromb Res. 1986;43:553-60.
109. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet. 2001;357:2023-4.
110. Prasad KS, Andre P, Yan Y, Phillips DR. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol. 2003;10:356-61.
111. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev. 1997;159:119-35.
112. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation - a workshop report. Placenta. 2005;26 (Suppl A):S114-7.
113. rocha-Pinango CL, Ojeda A, Lopez G, Garcia L, Linares J. beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) in obstetrical cases. Acta Obstet Gynecol Scand. 1985;64:115-20.
114. Romero R, Snyder E, Scott D, Oyarzun E, Hobbins JC, Duffy TP. Beta-thromboglobulin during normal pregnancy, labor, and puerperium. Am J Perinatol. 1988;5:109-12.
115. Russo S, Bussolati B, Deambrosis I, Mariano F, Camussi G. Platelet-activating factor mediates CD40-dependent angiogenesis and endothelial-smooth muscle cell interaction. J Immunol. 2003;171:5489-97.
116. Saleh AA, Bottoms SF, Farag AM, Dombrowski MP, Welch RA, Norman G, et al. Markers for endothelial injury, clotting and platelet activation in preeclampsia. Arch Gynecol Obstet. 1992;251:105-10.
117. Saleh AA, Gerbasi FR, Mammen EF, Farag A. Increased platelet activation in preterm labor. Thromb Res. 1992;65:475-7.
118. Sawdy R, Pan H, Sullivan M, Bennett P. Effect of selective vs. non-selective cyclo-oxygenase inhibitors on fetal membrane prostaglandin synthesis. J Obstet Gynaecol. 2003;23:239-43.
119. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
120. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8.
121. Shepherd DM, Kerkvliet NI. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation. J Immunol. 1999;163:2470-7.
122. Sixma JJ, Wester J. The hemostatic plug. Semin Hematol. 1977;14:265-99.
123. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008-14.
124. Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am. 2007;21:115-21.
125. Stjernholm-Vladic Y, Stygar D, Mansson C, Masironi B, Akerberg S, Wang H, et al. Factors involved in the inflammatory events of cervical ripening in humans. Reprod Biol Endocrinol. 2004;2:74.
126. Suarez CR, Gonzalez J, Menendez C, Fareed J, Fresco R, Walenga J. Neonatal and maternal platelets: activation at time of birth. Am J Hematol. 1988;29:18-21.
127. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000;164:6593-600.
128. Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents. 2004;18:172-7.
129. Tygart SG, McRoyan DK, Spinnato JA, McRoyan CJ, Kitay DZ. Longitudinal study of platelet indices during normal pregnancy. Am J Obstet Gynecol. 1986;154:883-7.
130. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;20;106:981-6.
131. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 1999;42:871-81.
132. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
133. van KC, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330-7.
134. Vecchiarelli A, Retini C, Pietrella D, Monari C, Kozel TR. T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol. 2000;30:1385-93.
135. Xu H, Arnaud F, Tadaki DK, Burkly LC, Harlan DM, Kirk AD. Human platelets activate porcine endothelial cells through a CD154-dependent pathway. Transplantation. 2001;72:1858-61.
136. Yin D, Ma L, Shen J, Byrne GW, Logan JS, Chong AS. CTLA-41g in combination with anti-CD40L prolongs xenograft survival and inhibits anti-gal ab production in GT-Ko mice. Am J Transplant. 2002;2:41-7.
137. Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T. Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. Obstet Gynecol. 2001;97:366-70.
138. Yoneyama Y, Suzuki S, Sawa R, Miura A, Doi D, Otsubo Y, et al. Plasma nitric oxide levels and the expression of P-selectin on platelets in preeclampsia. Am J Obstet Gynecol. 2002;187:676-80.
139. Zeller JA, Lenz A, Eschenfelder CC, Zunker P, Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol. 2005;25:1519-23.
140. Zhang Y, Cao HJ, Graf B, Meekins H, Smith TJ, Phipps RP. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol. 1998;160:1053-7.